Indomethacin

CHEMBL6 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
357.8 g/mol
LogP
4.3
Phase
4

This potent nonsteroidal anti-inflammatory drug (NSAID) is used to treat moderate-to-severe pain and inflammation in conditions such as arthritis, gout, bursitis, and tendinitis. It works by inhibiting cyclooxygenase (COX) enzymes that produce prostaglandins. In newborns, intravenous indomethacin is used to close a patent ductus arteriosus.

分子量

357.8000 g/mol

LogP

4.30

TPSA

68.50 Ų

リピンスキーの五則

適合

治療領域

作用機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1

InChI

InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)

Molecular Formula

C19H16ClNO4

HBD / HBA

1 / 4

回転可能結合数

4

重原子数

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This potent nonsteroidal anti-inflammatory drug (NSAID) is used to treat moderate-to-severe pain and inflammation in conditions such as arthritis, gout, bursitis, and tendinitis. It works by inhibiting cyclooxygenase (COX) enzymes that produce prostaglandins. In newborns, intravenous indomethacin is used to close a patent ductus arteriosus.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Indomethacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3715. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.